Corbus Pharmaceuticals (CRBP)

• Market cap: $142M
• 1 day: -3.16%
• 5 days: -16.92%
• 1 month: -24.01%
• 3 months: -10.62%
• 6 months: -33.62%
• Year to date: -2.67%
• 1 year: 4.08%
• 5 years: -87.48%
• 10 years: -91.49%
• Sector: Healthcare
• Industry: Biotechnology

About: Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Employees: 36